breast cancer, AstraZeneca and Daiichi Sankyo
Daiichi Sankyo Shares Jump After U.S. FDA Approves Breast Cancer Drug
Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39, on Monday after rising as much as 9.7% earlier. Over the past three years, the stock posted a daily gain of more than 8% only four times.
The U.S. Food and Drug Administration has officially banned red dye — called Red 3, or Erythrosine — from foods, dietary ...
Smithsonian Magazine on MSN3d
FDA Bans Red Dye No. 3 From Food, Beverages and Ingested Drugs, Citing Link to Cancer in Lab RatsAfter decades of debate, the Food and Drug Administration (FDA) has announced a ban on Red Dye No. 3, a synthetic food ...
On January 16, the U.S. Food and Drug Administration (FDA) announced that it is revoking the authorization for use of FD&C Red No. 3 in ...
On Wednesday, the Food and Drug Administration (FDA) issued an order that will ban Red No. 3, a synthetic dye, from food, ...
Rising diagnoses of certain cancers in people under 50 predate the rollout of COVID-19 vaccines by decades, undermining ...
The Food and Drug Administration (FDA) announced Wednesday it will ban Red No. 3, a common artificial food dye linked ...
The FDA has banned red dye No. 3 in food and ingested drugs, the agency announced. But what exactly is red dye No. 3, and why ...
Companies say they are working to update their products to comply with the Food and Drug Administration's decision Wednesday to ban the artificial food dye Red 3, after the agency said it was revoking ...
Already banned in cosmetics and topical medicines since 1990, the Food and Drug Administration announced on Wednesday that ...
The U.S. Food and Drug Administration (FDA) is taking a stronger approach toward supporting health goals in 2025 and beyond by setting the tone ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback